JAK2 is a critical therapeutic target in VEXAS syndrome treated with ruxolitinib.
Ceccardi A, Dameri M, Ravera F, Gilardi N, Stabile M, Lombardo I, Ceresa D, Colombo M, Vigo T, Cigolini B, Rivoli G, Dragani M, Solimano I, Garuti A, Bellodi A, Ballestrero A, Ferrando L, Zoppoli G.
Ceccardi A, et al. Among authors: colombo m.
Br J Haematol. 2025 Jan 15. doi: 10.1111/bjh.19979. Online ahead of print.
Br J Haematol. 2025.
PMID: 39814683
No abstract available.